Intelligent Ultrasnd - Notice of Results
31/07/2024 07:00
For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240731:nRSe4770Ya&default-theme=true
RNS Number : 4770Y Intelligent Ultrasound Group PLC 31 July 2024
Intelligent Ultrasound Group plc
(the "Group" or the "Company")
Notice of results
Analyst and investor briefing
Intelligent Ultrasound Group plc (AIM: IUG), the 'classroom to clinic'
ultrasound company, specialising in artificial intelligence (AI) software and
simulation, announces it will issue its interim results for the six months
ended 30 June 2024 on Wednesday, 14 August 2024.
A briefing for analysts will be held via video call on 14 August 2024 at
09:30am BST. To register, please contact intelligentultrasound@tbcardew.com
(mailto:intelligentultrasound@tbcardew.com)
The Company will host a live presentation for investors given by CEO Stuart
Gall and CFO Helen Jones via the Investor Meet Company platform on Wednesday,
14 August 2024 at 11:00am BST. The presentation is open to all existing and
potential shareholders. Questions can be submitted pre-event via your Investor
Meet Company dashboard up until 13 Aug 2024, 09:00am BST, or at any time
during the live presentation.
Investors can sign up to Investor Meet Company for free and add to meet the
Company via:
https://www.investormeetcompany.com/intelligent-ultrasound-group-plc/register-investor
(https://www.investormeetcompany.com/intelligent-ultrasound-group-plc/register-investor)
Investors who already follow Intelligent Ultrasound on the Investor Meet
Company platform will automatically be invited.
For further information, please contact:
Intelligent Ultrasound Group plc www.intelligentultrasound.com (http://www.intelligentultrasound.com)
Stuart Gall, CEO Tel: +44 (0)29 2075 6534
Helen Jones, CFO
Cavendish Capital Markets Limited
(Nominated advisor and broker)
Giles Balleny (Corporate Finance) Tel: +44 (0)20 7397 8900
Nigel Birks (ECM)
Dale Bellis (Sales)
TB Cardew - PR Advisors Intelligentultrasound@tbcardew.com (mailto:Intelligentultrasound@tbcardew.com)
Ed Orlebar Tel: +44 (0)7738 724630
Allison Connolly Tel: +44 (0)7587 453955
Emma Pascoe-Watson Tel: +44 (0)7774 620415
Jessica Pilling Tel: +44 (0)7918 584573
About Intelligent Ultrasound Group
Intelligent Ultrasound (AIM: IUG) is one of the world's leading 'classroom to
clinic' ultrasound companies, specialising in real-time hi-fidelity virtual
reality simulation for the ultrasound training market ('classroom') and
artificial intelligence-based clinical image analysis software tools for the
diagnostic medical ultrasound market ('clinic'). Based in Cardiff in
the UK and Atlanta in the US, the Group has two revenue streams:
Simulation
Real-time hi-fidelity ultrasound education and training through simulation.
Our main products are the ScanTrainer obstetrics and gynaecology training
simulator, the HeartWorks echocardiography training simulator,
the BodyWorks Eve Point of Care and Emergency Medicine training simulator
with Covid-19 module and the new BabyWorks Neonate and Paediatric training
simulator. To date over 1,700 simulators have been sold to over 800 medical
institutions around the world.
Clinical AI software
Deep learning-based algorithms to make ultrasound machines smarter and more
accessible using our proprietary ScanNav ultrasound image analysis technology.
Current products on the market utilising this technology are GE
HealthCare's SonoLyst software that is incorporated in their Voluson Expert
and SWIFT ultrasound machines; ScanNav Anatomy PNB that simplifies
ultrasound-guided needling by providing the user with real-time AI-based
anatomy highlighting for a range of medical procedures; and NeedleTrainer
that teaches real-time ultrasound-guided needling and incorporates ScanNav
Anatomy PNB.
www.intelligentultrasound.com (http://www.intelligentultrasound.com/)
NOTE: ScanNav Anatomy PNB is CE approved and cleared for sale in the US by the
FDA but is not available for sale in any other territory requiring government
approval for this type of product.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END NORMZGFNLGMGDZM